Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
:QNCX
RESEARCH TOOLSreports
Holding QNCX?
Track your performance easily
QNCX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.51 - $2.45
Previous CloseN/A
Volume30.57K
Average Volume (3M)188.79K
Market Cap
$75.68M
Enterprise Value$1.11M
Total Cash (Recent Filing)$7.34M
Total Debt (Recent Filing)$7.17M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 04, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding44,001,644
10 Day Avg. Volume151,278
30 Day Avg. Volume188,789
Standard Deviation0.29
R-Squared0.01
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$9.50Price Target Upside472.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Quince Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityQuince Therapeutics has sufficient cash to fund operations into early 2026, supporting its financial stability and ongoing research and development efforts.
Innovative Treatment PlatformQuince Therapeutics is advancing its AIDE technology platform that allows for encapsulation of a drug into a patient’s own red blood cells, offering potential innovative treatment options.
Regulatory MilestoneThe FDA granted a Special Protocol Assessment (SPA) for the P3 NEAT trial, which is a significant regulatory milestone for the program.
Bears Say
Safety ConcernsThree patients were discontinued from the study: one patient in the low-dose group had a serious adverse event (SAE) of B-cell lymphoma, and two patients in the high-dose group had treatment-emergent adverse events such as pyrexia, tachycardia, pain, and pruritus.
Study ChallengesThe EryDex P3 study stems from a prior miss in another P3 (ATTeST) while with EryDel, indicating previous challenges in achieving primary endpoints.
Study ResultsThe ATTeST study missed on the primary endpoint of intent-to-treat modified International Cooperative Ataxia Rating Scale.
---
Ownership Overview
18.09% Insiders
3.50% Mutual Funds
4.24% Other Institutional Investors
71.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $2.45 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $75.68M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 44 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.173 by $0.043.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 44,001,644 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.173. Following the earnings report the stock price went up 19.497%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
---
Quince Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (472.29% Upside)
$9.50 (472.29% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.57%
12-Months-Change
Fundamentals
Return on Equity
-83.18%
Trailing 12-Months
Asset Growth
48.17%
Trailing 12-Months
Company Description
Quince Therapeutics
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
---
QNCX Stock 12 Month Forecast
Average Price Target
$9.50
▲(472.29% Upside)
Technical Analysis
Avalo Therapeutics
―
BioVie
―
Cellectar Biosciences
―
Forte Biosciences
―
Hoth Therapeutics
―
Esperion
―
Best Analysts Covering QNCX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+103.50%
initiated a buy rating 3 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +103.50% per trade.
---